Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
synthetic corticotropin
- Development stage
- Preclinical
- Lead developer
- Amphastar Pharmaceuticals
- Modality
- Peptides
- Administration
- Intramuscular, Subcutaneous
01
Overview
Synthetic corticotropin is a 39 amino acid peptide designed to be gelatin-free and preservative-free. It functions as a hormonal agent, mimicking the action of naturally occurring corticotropin (adrenocorticotropic hormone or ACTH). This drug candidate was initially developed by Imprimis Pharmaceuticals and subsequently transferred to Eton Pharmaceuticals for further development and commercialization, utilizing the 505(b)(2) regulatory pathway.
- Other names
- gelatin-free and preservative-free 39 amino acid peptide synthetic corticotropin
02
Targets
MC2R (Adrenocorticotropic Hormone Receptor)
Beyond the preview
Go deeper on synthetic corticotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on synthetic corticotropin.